Targeting cancer cachexia: we're on the way
Menés sur 979 patients atteints d'un cancer avancé du poumon non à petites cellules et d'une cachexie, ces deux essais internationaux de phase III évaluent l'efficacité, du point de vue de l'évolution de la masse maigre de l'organisme et de la force de préhension, et la toxicité de l'anamoréline
Temel and colleagues report on the results of two phase 3 trials (ROMANA 1 and ROMANA 2) assessing the effects of anamorelin, a ghrelin-receptor agonist, on cancer cachexia in patients with advanced non-small-cell lung cancer receiving chemotherapy, radiotherapy, or both. The population was of a substantial size, and thus quite well representative of patients with non-small-cell lung cancer, with almost 978 participants enrolled and randomly assigned 2:1 to receive 100 mg of anamorelin or placebo once daily for 12 weeks.
The Lancet Oncology , commentaire, 2015